A DAPA-MI subanalysis finds dapagliflozin reduces new-onset diabetes after heart attack regardless of glucose or BMI, with most symptom benefit in prediabetes. PICO summary and commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.
A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.